LM2010_banner-logo

Hepatitis B Abstracts

Peginterferon

133. A Head-to-Head Comparison of Peginterferon α-2b Treatment Regimens in the Treatment of Chinese and South-East Asian Patients with HBeAg Positive Chronic Hepatitis B.
135. Safety and Tolerability of Extended (96 Weeks) Treatment with Peginterferon Alfa-2a [40KD] in Genotype D Patients with HBeAg-Negative Chronic Hepatitis B.
215. Shorter Duration and Lower Dose of Peginterferon Alfa-2a Therapy Results in Inferior Hbeag Seroconversion Rates Compared with the Duration and Dose of 48 Weeks and 180 µg: NEPTUNE Study.
479. Early On-Treatment HBsAg and HBV DNA Levels Identify HBeAg-Negative Patients Not Responding to 48 or 96 Weeks of Peginterferon Alfa-2a Therapy.
486. Serum HBsAg Levels Decrease Through Long-Term Follow-Up in HBeAg-Negative Patients Achieving a Sustained Response to Peginterferon Alfa-2a.
489. Stronger HBV DNA Suppression in Patients with HBeAg-Positive Chronic Hepatitis B Achieving HBeAg Clearance During Peginterferon Alfa-2b Therapy Compared with Placebo.

· Adefovir

o 484. Adding Adefovir Compared with Switching to Entecavir in Patients with Lamivudine-Resistant Chronic Hepatitis B (ACE Study) - A Multicenter Prospective Randomized Study: One-Year Interim Analysis.

· Entecavir

o 478. Long-Term Entecavir Treatment for up to 5 Years in Asians with HBeAg-positive Nucleos(t)ide naïve Chronic Hepatitis B: Results from ETV-022 and -901. (Updated October 31, 2010)

o 485. Efficacy and Safety of Entecavir in Nucleos(t)ide Naïve Asians with HBeAg-Positive and -Negative Chronic Hepatitis B: Results from Studies ETV-022/027. (Updated October 31, 2010)

· Telbivudine

o 212. A Prospective and Open-Label Study for the Efficacy and Safety of Telbivudine(Ltd) in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus (HBV) to the Infants.

o 491. Telbivudine Switch in Lamivudine Pretreated Chronic Hepatitis B Patients Provides Sustained Viral Suppression for 2 Years.

· Tenofovir

o 134. HBV rtN236T Mutant Subpopulations Respond Like Wild-Type During Tenofovir DF (TDF) Monotherapy or Combination Therapy with Emtricitabine (FTC): an Evaluation of Early Viral Load Decay Kinetics.

o 136. Tenofovir Disoproxil Fumarate (TDF) Versus Emtricitabine Plus TDF (FTC/TDF) for Treatment of Chronic Hepatitis B (CHB) In Patients with Persistent Viral Replication Receiving Adefovir Dipivoxil: Final Week 168 Results.

o 137. 4 Year Efficacy of Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B Patients with High Viral Load (HBV DNA ≥9 log₁₀ copies/mL): Preliminary Analysis.

o 138. Tenofovir (TDF) for Chronic Hepatitis B Patients with Suboptimal Response to Adefovir (ADV) or ADV/LAM Treatment: Results of the OptiB Italian Multicenter Prospective Open Label Study.

o 476. Continued Efficacy and Safety Through 4 Years of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Negative Patients with Chronic Hepatitis B (Study 102): Preliminary Analysis

o 477. Long Term (4 Year) Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg-Positive Patients (HBeAg+) with Chronic Hepatitis B (Study 103): Preliminary Analysis.

o 481. Four Years Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Asians with HBeAg-positive and HBeAg-negative Chronic Hepatitis B (CHB), Preliminary Analysis.

Miscellaneous

· LB-17. Immunogenicity of Two Doses of Investigational HEPLISAV™ (HBsAg-ISS) Compared to Three Doses of Licensed Hepatitis B Vaccine (ENGERIX-B®) in Diabetics.